Dihydrotanshinone: A Pan-Therapeutic Treatment for Chemoresistance in Cancer
ISEF · 2018 Biomedical and Health Sciences Third Award
Overview
Glioblastoma is the most common and aggressive type of brain tumor in adults, primarily treated with the chemotherapeutic agent Temozolomide (TMZ). However, many tumors are initially resistant to or develop resistance to TMZ, mainly due to high levels of O6-methylguanine DNA transferase (MGMT), which repairs the DNA damage caused by TMZ. Research reported here focused on reversing TMZ resistance by combinatorial treatment with Dihydrotanshinone (DHT), an analogue of which is currently in clinical trials for childhood leukemia (APL). DHT in combination with TMZ displayed a synergistic, selectively cytotoxic, oncolytic effect in a MGMT-deficient cell line and a sensitizing effect to TMZ in a MGMT-expressing cell line, as confirmed by the Combination Index Synergy Algorithm. Cytotoxicity due to DHT was shown to be reactive oxygen species dependent, as suggested by a computational molecular docking model. Importantly, DHT was shown to penetrate the blood-brain barrier in a novel in vitro co-culture model, verified by the TEER method and various permeability dyes. The interaction between DHT and TMZ was found to be a result of the synergistic reduction of protein and mRNA expression of MGMT and P-glycoprotein, a critical drug transport channel. Differential gene expression was assessed via DNA microarray and protein expression via enzyme linked immunosorbent assay. Additionally, the NfkB complex and AKT activity were sensitive to combinatorial treatment, revealing the mechanism of action of the combinatorial strategy. DHT was shown to augment TMZ efficacy, indicating that, since DHT can penetrate the blood–brain barrier, TMZ in combination with DHT may represent a promising therapeutic option for glioblastoma.
Awards (1)
- Third Award of $1,000 $1,000
Competition history
- ISEF 2018
Resources
Related projects
ISEF · 2019
TMZ+X: siRNA-based Synthetic Lethal Screening and Synergism with TMZ as a Novel Approach to Inhibition of Proliferation in GBM
ISEF · 2023
Sulforaphane and Panobinostat: A Novel Therapy for Glioblastoma Multiforme
ISEF · 2014
Targeting Brain Tumor Stem Cells through Natural Antioxidants
ISEF · 2021
A Novel Efflux Pump Inhibitor Improves Chemotherapeutic Efficacy Against P-glycoprotein-expressing Glioblastoma Stem Cells
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair